David Karasek, Jaromira Gajdova, Veronika Kubickova, Ondrej Krystyni, Lubica Cibickova and Helena Vaverkova
University Hospital Olomouc, Czech Republic
Scientific Tracks Abstracts: J Diabetes Metab
Introduction: Adiponectin, adipocyte fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF-21), C1q/TNF-related protein 9 (CTRP9) and allograft inflammatory factor-1 (AIF-1) differently contribute to oxidative stress, chronic inflammation, insulin resistance and vascular damage. The aim was to compare their levels in patients with type 2 diabetes and in healthy controls and to determine their relationship to markers of endothelial dysfunction and arterial stiffness. Methods: 54 patients with type 2 diabetes (32 men, 22 women) and 21 healthy controls (8 men, 13 women) were included in the study. Adipokines, lipids, anthropological parameters, indicators of insulin resistance and also soluble markers of endothelial dysfunction - von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) were measured. Augmentation index (AI) and pulse wave velocity PVW measured by SphygmoCor served as markers of arterial stiffness. Results: Type 2 diabetics had significantly higher levels of A-FABP [50.0 (38.1-68.6) versus 28.6 (23.6-32.9) mg/l, p<0.001], vWF [133.1 (110.7-163.2) versus 98.5 (84.4-125.0)%, p<0.01] and PAI [78.1 (41.2-106.5) versus 36.9 (27.5-41.9) ng/ml, p<0.001] and lower levels of adiponectin [5.9 (4.3-9.0) versus 11.3 (8.7-14.8) mg/l, p<0.001] compared to healthy controls. Differences in other adipokines were not statistically significant. Adiponectin correlated negatively with vWF levels (r=-0.29, p<0.05) and PAI-1 (r=-0.35, p<0.01), A-FABP positively with vWF (r=0.45, p<0.01) PAI-1 (r=0.46, p<0.01) and augmentation index (r=0.39, p<0.01). The levels of FGF-21 correlated only with PAI-1 (r=0.27, p<0.05). Conclusion: Patients with type 2 diabetes have significantly higher levels of A-FABP and lower levels of adiponectin. These adipokines correlate with markers of vascular damage and may interfere with the cardiovascular risk of these individuals.
David Karásek is an associate professor of Internal Medicine at Faculty of Medicine and Dentistry of Palacky University in Olomouc, Czech Republic. He works as Deputy Head of Third Department of Internal Medicine – Nephrology, Rheumatology and Endocrinology of University Hospital Olomouc. He manages the Center for diabetes of University Hospital Olomouc and as specialist doctor is involved in the activities of the Clinic for endocrine diseases and the Center for lipid metabolism disorders. His research is focused on the issue of dyslipidemia, metabolic syndrome, insulin resistance, visceral obesity and their relationship to early cardiovascular involvement. He is the author or co-author of several chapters in monographs or textbooks and of about one hundred scientific papers. He is the editorial board member for the two scientific journals. For his research, he received a number of medical awards (Prizes of the Czech Society for Internal Medicine, Czech Society for Atherosclerosis, Czech Diabetes Society) and the Minister of Health of the Czech Republic Prize for research and development.
Email: david.b.karasek@gmail.com
